Mergers & Acquisitions

Oncology, driven by the promise of IO, dominates biopharma deals landscape

Spurred by the promise of immuno-oncology (IO), oncology dominated the biopharma dealmaking landscape last year, a new article by Jamie Munro and Helen Dowden, of Clarivate Analytics, shows. The acute interest in IO continues a trend, the article noted: The technology has been a factor in 32 of the 35 multibillion-dollar oncology licensing deals over […]

Life sciences M&A deals in the fourth quarter of 2017: updates and trends

During the fourth quarter of 2017, Cortellis Deals Intelligence registered 122 new mergers and acquisitions (M&A) with a total disclosed deal value of $92.3 billion as part of its ongoing coverage of M&A activity in the life sciences sector compared to 121 and $30.1 billion in the third quarter and 111 and $22 billion in […]

As biopharma innovation accelerates, partnering follows suit

Last year was a mixed bag for biopharma dealmaking, and not just by the numbers. Lofty valuations tamped down M&A, with buy-side companies also awaiting the outcome of U.S. tax reform. Oncology assets continued to rule, although first-in-class approvals actually showed a decline. And with orphan indications continuing to dominate drug development efforts, the biopharma […]

Interventional Oncology – here come the big guns

One of the fastest-growing and most dynamic markets covered by the medtech team here at DRG is the field of interventional oncology. Although both ablation devices (used to a heat, cool or even electrocute tumor tissue in order to destroy it) and embolization particles (used to plug up vessels feeding tumors, in order to control […]